| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 681.25% | Roth MKM | → $7 | Initiates Coverage On | → Buy |
| 06/07/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 04/18/2023 | 681.25% | Oppenheimer | $12 → $7 | Maintains | Outperform |
| 03/10/2022 | 2132.14% | Oppenheimer | $30 → $20 | Maintains | Outperform |
| 12/07/2021 | 3248.21% | Aegis Capital | → $30 | Initiates Coverage On | → Buy |
| 05/26/2021 | 4922.32% | Cantor Fitzgerald | → $45 | Initiates Coverage On | → Overweight |
| 05/07/2021 | 4587.5% | Oppenheimer | → $42 | Initiates Coverage On | → Outperform |
What is the target price for Chemomab Therapeutics (CMMB)?
The latest price target for Chemomab Therapeutics (NASDAQ: CMMB) was reported by Roth MKM on October 6, 2023. The analyst firm set a price target for $7.00 expecting CMMB to rise to within 12 months (a possible 681.25% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
The latest analyst rating for Chemomab Therapeutics (NASDAQ: CMMB) was provided by Roth MKM, and Chemomab Therapeutics initiated their buy rating.
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a initiated with a price target of $0.00 to $7.00. The current price Chemomab Therapeutics (CMMB) is trading at is $0.90, which is within the analyst's predicted range.